TY - JOUR T1 - Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex JF - Drug Metabolism and Disposition JO - Drug Metab Dispos SP - 888 LP - 896 DO - 10.1124/dmd.118.080952 VL - 46 IS - 6 AU - Deepak Kumar Bhatt AU - Abdul Basit AU - Haeyoung Zhang AU - Andrea Gaedigk AU - Seung-been Lee AU - Katrina G. Claw AU - Aanchal Mehrotra AU - Amarjit Singh Chaudhry AU - Robin E. Pearce AU - Roger Gaedigk AU - Ulrich Broeckel AU - Timothy A. Thornton AU - Deborah A. Nickerson AU - Erin G. Schuetz AU - John K. Amory AU - J. Steven Leeder AU - Bhagwat Prasad Y1 - 2018/06/01 UR - http://dmd.aspetjournals.org/content/46/6/888.abstract N2 - The major objective of this study was to investigate the association of genetic and nongenetic factors with variability in protein abundance and in vitro activity of the androgen-metabolizing enzyme UGT2B17 in human liver microsomes (n = 455). UGT2B17 abundance was quantified by liquid chromatography-tandem mass spectrometry proteomics, and enzyme activity was determined by using testosterone and dihydrotestosterone as in vitro probe substrates. Genotyping or gene resequencing and mRNA expression were also evaluated. Multivariate analysis was used to test the association of UGT2B17 copy number variation, single nucleotide polymorphisms (SNPs), age, and sex with its mRNA expression, abundance, and activity. UGT2B17 gene copy number and SNPs (rs7436962, rs9996186, rs28374627, and rs4860305) were associated with gene expression, protein levels, and androgen glucuronidation rates in a gene dose-dependent manner. UGT2B17 protein (mean ± S.D. picomoles per milligram of microsomal protein) is sparsely expressed in children younger than 9 years (0.12 ± 0.24 years) but profoundly increases from age 9 years to adults (∼10-fold) with ∼2.6-fold greater abundance in males than in females (1.2 vs. 0.47). Association of androgen glucuronidation with UGT2B15 abundance was observed only in the low UGT2B17 expressers. These data can be used to predict variability in the metabolism of UGT2B17 substrates. Drug companies should include UGT2B17 in early phenotyping assays during drug discovery to avoid late clinical failures. ER -